• Journal of Chest Surgery
• /
• 제16권4호
• /
• pp.458-469
• /
• 1983

Between October, 1978, and December, 1982, Glutaraldehyde-stablized pericardial xenografts [Ionescu-Shiley valve] were used for heart valve replacement in 409 patients.[251 mitral, 49 aortic, 11 tricuspid, and 98 multiple valve replacement]. There were 31 early deaths [7.6%], and 371 operative survival were observed for a total of 507.6 years over a period of 1 to 44 months. [mean 17 months]. Actuarial analysis of late results indicates an excepted survival rate at 4 years of 86.25.4% for patients with mitral, 79.37.1% for patients with aortic valve replacement. Actuarial survival rates for total patients at 4 years was 77.88.2%. The rate of systemic embolism has been 1.6% per patient-year for mitral and 1.8% per patient-year for aortic group in the presence of anticoagulation treatment. Among the 6 embolic episodes, 2 patients were died. The incidence of hemorrhagic complication was 1.3% per patient-year for anticoagulated patients. There were 6 confirmed valve failures, five in mitral and one in aortic position. Re-replacement of destructed valve was performed in one patient and others were treated medically. Among the 6 episodes, 3 occurred in children [Below 15 years], it account almost 9 times higher than adult. Our clinical data compare very favorable with those obtained with other available prostheses and tissue valves, but it should be considered to give short-term anticoagulation therapy to hemodynamically stable patients and aortic valve patients, and other prosthetic valve must be considered to use in children.

• Journal of Chest Surgery
• /
• 제56권6호
• /
• pp.394-402
• /
• 2023

Background: The optimal choice of valve substitute for aortic valve replacement (AVR) in pediatric patients remains a matter of debate. This study investigated the outcomes following AVR using mechanical prostheses in children. Methods: Forty-four patients younger than 15 years who underwent mechanical AVR from March 1990 through March 2023 were included. The outcomes of interest were death or transplantation, hemorrhagic or thromboembolic events, and reoperation after mechanical AVR. Adverse events included any death, transplant, aortic valve reoperation, and major thromboembolic or hemorrhagic event. Results: The median age and weight at AVR were 139 months and 32 kg, respectively. The median follow-up duration was 56 months. The most commonly used valve size was 21 mm (14 [31.8%]). There were 2 in-hospital deaths, 1 in-hospital transplant, and 1 late death. The overall survival rates at 1 and 10 years post-AVR were 92.9% and 90.0%, respectively. Aortic valve reoperation was required in 4 patients at a median of 70 months post-AVR. No major hemorrhagic or thromboembolic events occurred. The 5- and 10-year adverse event-free survival rates were 81.8% and 72.2%, respectively. In univariable analysis, younger age, longer cardiopulmonary bypass time, and smaller valve size were associated with adverse events. The cut-off values for age and prosthetic valve size to minimize the risk of adverse events were 71 months and 20 mm, respectively. Conclusion: Mechanical AVR could be performed safely in children. Younger age, longer cardiopulmonary bypass time and smaller valve size were associated with adverse events. Thromboembolic or hemorrhagic complications might rarely occur.

• Journal of Chest Surgery
• /
• 제33권8호
• /
• pp.643-647
• /
• 2000

From March 1988 to June 1994, 275 CarboMedics cardiac valve prostheses(199 mitral, 70 aortic and 3 tricuspid) were implanted in 226 consecutive patients(mean age 39 years, male/female 90/136) by one surgical team operating on adult cardiac patients at Kyungpook University Hospital. Total follow up represented 16,848 patient-months(mean 76 months) and follow up rate was 96%. One hundred and forty-nine patients(66%) wer in NYHA functional class III or IV preoperatively, and 204 patients(99.5%) were in class I or II postoperatively. Early mortality was 4.9% and late death was 9.3%. The actuarial survival at 81 months was 86.l2$\pm$3.1%. The linearized incidence of valve-related death, prosthetic valve thrombosis, anticoagulation-related hemorrhage, non-structural dysfunction and reoperation were 0.71%, 0.43%, 0.07%, 0.21%, and 0.14% respectively. The 81-month rate of freedom from all valve related complications and deaths including hospital mortality was 88.1$\pm$2.5%. Thee facts suggest that the CarboMedics cardiac valve has excellent result, low incidence of valve-related complications and no structureal deterioration.

• 대한의용생체공학회:의공학회지
• /
• 제17권2호
• /
• pp.215-220
• /
• 1996

Impact force and strains induced by impact between the occluder and the struts have been measured with force sensor and strain gages. The maximum reaction force was about 25N, and the calculated impact force on the root of the struts amount about 9-17W. Impact force on the inlet strut is greater than that of the outlet strut, but the strain on the outlet strut is much higher than that of the inlet strut. These values might cause severe damage on the valve in the critical cases. The results of this study may be extended for the analysis of the endurance limit and optimal design of the struts and occluder.

• Journal of Chest Surgery
• /
• 제34권9호
• /
• pp.680-685
• /
• 2001

배경: 삼첨판막친환술은 매우 드물게 시행되는 수술이며 그 장기 성적은 만족치 못한 수준이다. 또한 어떤 종류의 인공판막을 사용하느냐에 대하여도 논란이 많은 상황이다. 서울대학교병원 흉부외과에서는 1989년 1월부터 1998년 12월까지 10년동안 71명의 환자에서 72례의 삼첨판막 치환술을 시행하였으며 이 결과를 토대로 장단기 성적과 위험요인들을 분석하였다. 대상 및 방법: 평균나이는 42$\pm$13세(16~65세)였으며 남여비는 32/39였다. 술전진단은 50례의 후천성판막질환과 18례의 선천성심장질환이 있었고 삼첨판폐쇄부전만 단독으로 있었던 경우도 4례 있었다. 사용된 인공판막은 기계판막이 69개, 조직판막이 3개였다. 승모판막치환술 또는 대동맥판막치환술과 같이 시행된 경우는 50례였고 1례에서는 폐동맥판막 치환술이 같이 시행되었다. 결과: 조기사망은 7례(9.7%), 만기사망은 7례(13.0%)였고 10년 생존율은 59.2$\pm$7.2%였다. 삼천판막혈전증은 5례에서 11번에 결쳐 발생하였으며 그중 1례는 재수술을 시행받았다. 생존자들의 대부분은 심장기능분류 I-II의 상태로 현재까지 외래 추적관찰중이다. 결론: 삼첨판막치환술은 비록 혈전증등의 위험이 상존하기는 하지만 비교적 낮은 사망률과 이환율을 보이고 있으며 기계판막의 경우에도 조직판막과 비교하여 큰 차이 없이 좋은 장기성적을 얻을 수 있었다.

• 대한의용생체공학회:학술대회논문집
• /
• 대한의용생체공학회 1996년도 춘계학술대회
• /
• pp.167-171
• /
• 1996

Impact force and strains induced by impact between the occluder and the struts have been measured with force senfor and strain gages. The maximum reaction force was about 25N, and the calculated impact force on the root of the struts amount about $9{\sim}17N$. Impact force on the inlet strut is greater than that of the outlet strut, but the strain on the outlet strut is much higher than that of the inlet strut. These values might cause severe damage on the valve in the critical cases. The results of this study may be extended for the analysis of the endurance limit and optimal design of the struts and occluder.

• Journal of Chest Surgery
• /
• 제36권7호
• /
• pp.463-471
• /
• 2003

대동맥판막 치환술과 동반시행한 승모판막 성형술의 장기 결과에 대해서는 잘 알려져 있지 않다. 본 연구는 대동맥판막 및 승모판막 질환에서의 대동맥판막 치환술과 동반시행한 승모판막 성형술의 조기 및 장기 수술 결과에 대해 알아보고자 하였다. 대상 및 방법: 1990년 9월부터 2002년 4월까지 세종병원에서 대동맥판막 치환술과 승모판막 성형술을 받은 45명의 환자를 대상으로 후향적으로 조사하였다. 남녀비는 28 : 17명이었고 평균 연령은 47$\pm$17세였다. 심방세동은 12명에서 있었고 3명은 과거에 심장수술을 받았다. 승모판막 질환은 폐쇄부전 34명, 협착 3명, 폐쇄부전 및 협착 혼합형이 8명이었다. 승모판막 질환의 원인으로는 류머치스성 24명, 퇴행성 11명, 기능성 8명, 허혈성과 심내막염이 각각 1명이었으며 수술 소견상 판륜확장 31명, 건삭확장 19명, 판첨비후 19명, 교련응합 13명, 건삭융합 10명, 건삭판열 6명 등이었다. 수술은 모든 환자에서 대동맥판막(기계판막 32명, 조직판막 12명, 폐동맥자가판막 1명)을 치환하였고 승모판막 성형술은 판륜성형술이 32명에서, 판첨성형술은 29명에서 54건이 시행되었다. 총체외순환시간 및 대동맥차단시간은 각각 204$\pm$62분, 153$\pm$57분이었다. 결과: 조기사망은 1명(2.2%)으로 술 후 저심박증후군으로 사망하였다. 57$\pm$37개월을 추적조사한 결과 1명(2.3%)이 암으로 사망하였으며 10년 actuarial survival 96$\pm$4%였다. 승모판 폐쇄부전은 11명에서 II혹은 III를 보였고, 중등도의 승모판 협착은 3명에서 있었으며 판막 관련 재수술은 2명에서 승모판막 질환으로 1명에서 대동맥판막 질환으로 필요하였다. 승모판막 폐쇄부전과 협착으로부터의 자유도는 각각 64$\pm$11%와 86$\pm$8%였으며 재수술로부터의 자유도는 89$\pm$7%였다. 결론: 대동맥판막 치환술과 동반시행한 승모판막 성형술은 양호한 조기 및 장기 생존율을 보이며 향후 승모판막 폐쇄부전 및 협착 재발률을 더 낮추기 위해서는 특히 류머치스성 승모판막 질환 경우에는 성형술에 대한 적절한 술기 및 적응증의 선택이 중요하리라 생각된다.

• Journal of Chest Surgery
• /
• 제33권2호
• /
• pp.146-150
• /
• 2000

background: The prognosis after an aortic valve replacment can be affected significantly by the transprosthetic pressure gradient which is determined mainly by the size of the patients body and the prosthesis used. We analyzed the hemodynamic feature of two relatively new prosthese the ATS and the evensized Medtronic-Hall(M-H) valves by measuring the transprosthetic pressure gradient in the cases where small sizes (23mm or smaller) were used. Material and method: There were 94 patients who received whom aortic valve replacement with prosthesis smaller than 23 mm from October 1994 to June 1998. In these patients the transprosthetic pressure gradient clalculated from the pressure half time during postoperative Dopper echocardiographic examination was compared between the prostheses of different sizes. The body surface area of each patient was also taken into consideration. result: The mean pressure gradient and body surface area in each group were 21.7$\pm$10.2 mmHg and 1.52$\pm$0.14m2 in ATS 19mm 11.4$\pm$6.5 mmHg and 1,57$\pm$0.20m2 in M-H 20mm 15.2$\pm$6.3 mmHg and 1.54$\pm$0.13m2 in ATS 21mm 9.3$\pm$2.5 mmHg and 1.63 $\pm$0.14m2 in M-H 22 mm and 12.9$\pm$5.3 mmHg and 1.69$\pm$0.13m2 in ATS 23mm. Conclusion: The 19mm ATS prosthesis showed significant trasprosthetic pressure gradient which is similar to the values previously reported with other bileaflet prosthesesm Close follow-up was needed in terms of exercise capacity and change in left ventiricular geometry. In patients with small aortic valve annulus the 20mm M-H valve is recomendable as an alternative to 19mm bileaflet valves because it has less pressure gradient with similar outer diameter.

• Korean Circulation Journal
• /
• 제54권1호
• /
• pp.43-56
• /
• 2024

Background and Objectives: The therapeutic strategy for inflammation and degenerative calcification is of utmost importance for bioprosthetic heart valve (BHV) implanted patients. The purpose of this study was to compare the anti-inflammatory and anti-calcification effects of Entelon150^® (grape seed extract), losartan, and rosuvastatin, in a rabbit model of intravascular BHV leaflet implantation in bovine pericardium. Methods: A total of 28 rabbits were implanted with BHV leaflet in the external jugular veins. The Entelon150^® group was administered 7.7 mg/kg Entelon150^® twice daily for 6 weeks after surgery. The losartan and rosuvastatin groups received 5.14 mg/kg and 1 mg/kg, respectively, once per day. The control group received 1 ml of saline once daily. And then, calcium concentration was measured in the implanted BHV, and histological and molecular analyses were performed on the surrounding tissues. Results: The calcium content of the implanted tissue in the Entelon150^® group (0.013±0.004 mg/g) was lower than that in the control group (0.066±0.039 mg/g) (p=0.008). The losartan (0.024±0.016 mg/g, p=0.032) and rosuvastatin (0.022±0.011 mg/g, p=0.032) groups had lower calcium content than the control group, and higher tendency than the Entelon150^® group. Immunohistochemistry revealed that the expressions of bone morphogenic protein 2 (BMP2), S-100, and angiotensin II type 1 receptor in the Entelon150^® group showed lower tendency than those in the control group. The protein expression levels of BMP2 were reduced in the Entelon150^® group compared with those in the control group. Conclusions: Entelon150^® exhibited a significant effect, similar to other drugs, in reducing calcification and inflammation in the intravascular bovine pericardium.

• Journal of Chest Surgery
• /
• 제24권7호
• /
• pp.663-668
• /
• 1991

To evaluate risks, complications and mortality of reoperations on heart valve prosthesis, we reviewed clinical records of 53 patients who underwent reoperation because of prosthetic valve failure[PVF], from Jan 1959 through Jun. 1991. They had undergone 48 mitral, 10 aortic valve rereplacement Primary tissue failure was the main cause of reoperation : it occurred in 51 valves at a mean postoperative interval of 58 months. Calcification and collagen disruption of prosthesis were main causes of primary tissue failure in macro and micropathology, In 3 failing mechanical prostheses, paravalvular leak was in 2 cases, another one case had the thrombi at the hinge portion. If conditions such as emergency operation with or without endocarditis, thromboembolism and advanced NYHA functional class are prevented, we think that reoperative valve replacement has similar morbidity and mortality to initial valve replacement surgery. But our sturdy represents higher mortality [22.6%] because of late surgical intervention failing the prevention of conditions leading to myocardial damage. In conclusion if the tearing, calcification, and a new murmur were detected the early reoperation should be considered to increase late survival.